Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biopharmx Corp (BPMX)

Biopharmx Corp (BPMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Timber Pharmaceuticals Announces Investor Conference Call

Call to be held on Tuesday, May 26 at 11:00am EDT

BPMX : 0.5100 (-9.49%)
BioPharmX Announces 1-for-12 Reverse Stock Split Merger Transaction Expected to Close on May 18, 2020

, /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX" or the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced...

BPMX : 0.5100 (-9.49%)
BioPharmX Corporation Announces Approval of Merger by Stockholders at Special Meeting

, /PRNewswire/ --  (NYSE American: BPMX) today announced that all proposals related to its proposed merger with Timber Pharmaceuticals LLC ("Timber") were approved by BioPharmX's stockholders at a special...

BPMX : 0.5100 (-9.49%)
BioPharmX Corporation Urges Stockholders to Vote Now on Proposed Merger with Timber Pharmaceuticals

CAMPBELL, Calif., /PRNewswire/ -- (NYSE American: BPMX) is urging its stockholders to vote now on the proposed merger of BioPharmX with Timber Pharmaceuticals LLC ("Timber") and related matters as described...

BPMX : 0.5100 (-9.49%)
BioPharmX Corporation Announces that its Special Stockholders' Meeting will now be held on Wednesday, May 13, 2020 at 10:00 AM eastern time

BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX") today announced that the date of its special stockholders' meeting to consider and vote on the proposed merger of BioPharmX with Timber Pharmaceuticals...

BPMX : 0.5100 (-9.49%)
Timber Pharmaceuticals Announces Award of Second Tranche of FDA Orphan Products Clinical Trials Grant

Timber Pharmaceuticals LLC ("Timber"), a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced the company...

BPMX : 0.5100 (-9.49%)
BioPharmX Receives Notice of Delisting from NYSE American But Stock will Remain Trading

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received notification on March 24, 2020 from...

BPMX : 0.5100 (-9.49%)
BioPharmX And Timber Pharmaceuticals Announce Entry into Merger Agreement

BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX") and Timber Pharmaceuticals LLC ("Timber"), a privately held biopharmaceutical company focused on the development and commercialization of treatments...

BPMX : 0.5100 (-9.49%)
BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate Update

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended...

BPMX : 0.5100 (-9.49%)
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on September 19, 2019 from...

BPMX : 0.5100 (-9.49%)
BioPharmX Reports Fiscal Second Quarter 2020 Financial Results and Provides Corporate Update

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended...

BPMX : 0.5100 (-9.49%)
BioPharmX Announces Steven M. Bosacki Joins the Company as Chief Operating Officer

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announces the appointment of Steven M. Bosacki, a 20...

BPMX : 0.5100 (-9.49%)
Thinking about buying stock in Allergan, Biopharmx, Beyond Meat, Immunic, or Riot Blockchain?

InvestorsObserver issues critical PriceWatch Alerts for AGN, BPMX, BYND, IMUX, and RIOT.

AGN : 193.02 (+0.02%)
BPMX : 0.5100 (-9.49%)
RIOT : 2.34 (-7.87%)
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced positive results from its Phase 2b clinical...

BPMX : 0.5100 (-9.49%)
BioPharmX Announces Reverse Stock Split

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that its Board of Directors...

BPMX : 0.5100 (-9.49%)
Research Report Identifies TTM Technologies, Zumiez, Global Net Lease, Catabasis Pharmaceuticals, BioPharmX, and Protalix BioTherapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TTM Technologies, Inc. (NASDAQ:TTMI),...

TTMI : 11.44 (-1.38%)
ZUMZ : 25.38 (-4.91%)
GNL : 16.43 (-2.38%)
CATB : 6.49 (-2.84%)
BPMX : 0.5100 (-9.49%)
PLX : 3.54 (-0.28%)
BioPharmX Announces $3.9 Million Offering

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase...

BPMX : 0.5100 (-9.49%)
BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced presentations at multiple upcoming investor...

BPMX : 0.5100 (-9.49%)
BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter and year ended...

BPMX : 0.5100 (-9.49%)
BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has completed enrollment of its Phase...

BPMX : 0.5100 (-9.49%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +1.37 , SEDG -0.74 , THC -0.92 , TER +0.71 , LITE +1.63
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar